Gland Pharma trades at 30x EV/Ebitda for FY23, which is largely in line with some of its peers such as Syngene and Divi's Lab. Though we believe success in complex injectables holds further re-rating potential, here’s why we remain constructive on this steady earnings compounder and believe investors can accumulate during market-wide gyrations.
first published: Jul 22, 2021 07:18 pm
A collection of the most-viewed Moneycontrol videos.
Samvat 2082 LIVE | Muhurat Trading LIVE | Diwali 2025 | Investment Strategies
Samvat 2082: What To Expect In The New Year | Diwali Muhurat Trading
Diwali Cheer Extends For Fourth Day| Nifty Hits 25,900 Intra-day, Banks Party| Closing Bell Live
India’s top private bankers reveal where the next 100-baggers will emerge
Is it a good time to enter Bajaj Finance post Q3 business update? | Opening Bell
Attractive valuation, strong earnings potential: Buy this stock for the long term | Ideas for Profit
Vesuvius India made fresh lifetime high. Right time to buy the stock or wait for a drop?
Indian Hotel Industry Sees Strong Demand; Buy This Stock For Sector Upcycle | Ideas For Profit
Can strong auto demand drive this company’s stock further? | Ideas For Profit
